According to the UnivDatos, the surge in the incidence of AMD population and the rise in demand for innovative therapies will drive the global scenario of Age-related Macular Degeneration. As per their “Age-related Macular Degeneration Market” report, the global market was valued at USD 11 billion in 2023, growing at a CAGR of about 7.5% during the forecast period from 2024 - 2032 to reach USD billion by 2032. 

Age-related Macular Degeneration in North America has experienced significant growth in recent years, driven by various factors such as the increasing incidence of AMD supplemented by rising geriatric population, rising adoption of innovative therapies, and new product launches, etc.  North America, particularly the U.S., represents one of the largest markets for Age-related Macular Degeneration globally. Here's a detailed overview:

Access sample report (including graphs, charts, and figures): https://univdatos.com/reports/age-related-macular-degeneration-market?popup=report-enquiry

Driving Factors for the Market in North America:

The market for age-related macular degeneration (AMD) in North America is expanding significantly, mostly due to the condition's increasing prevalence. One of the main causes of vision loss in adults 50 years of age and older is age-related macular degeneration, a condition whose prevalence is rising with aging. The National Eye Institute estimates that 2.07 million Americans had AMD in 2020; as the population ages, this figure is projected to rise to 5.44 million by 2050.

The growing number of AMD cases emphasizes the critical need for cutting-edge therapeutic options and efficient treatments. Demand for cutting-edge medications, diagnostic equipment, and cutting-edge treatment alternatives including anti-VEGF medicines and retinal implants is being driven by the expanding patient pool. Furthermore, rising awareness about the condition and its management is also contributing to market expansion.

Importance of AMD Therapies

AMD therapies are vital for several reasons:

Vision Preservation: The primary goal of AMD therapies is to preserve and, in some cases, improve vision, thereby maintaining patients' independence and quality of life.

Disease Management: Effective therapies help manage the progression of AMD, delaying severe vision loss and the associated psychological and social impacts.

Innovative Research: Ongoing research and development in AMD therapies drive innovation in ophthalmology, leading to new treatments that offer hope for better outcomes.

1. Anti-VEGF Agents:

The most significant breakthrough in AMD treatment has been the development of anti-vascular endothelial growth factor (anti-VEGF) therapies. These drugs work by inhibiting the abnormal blood vessel growth and leakage in the retina, which are hallmark features of wet AMD.

Ranibizumab (Lucentis):

Approved by the FDA in 2006, Ranibizumab is a monoclonal antibody fragment designed to bind and inhibit VEGF-A, thereby reducing the growth of abnormal blood vessels. Clinical trials have shown that monthly injections of Ranibizumab can significantly improve vision in patients with wet AMD.

Aflibercept (Eylea):

Approved in 2011, Aflibercept acts as a VEGF trap, binding to VEGF-A and placental growth factor (PlGF), thereby preventing these factors from stimulating abnormal blood vessel growth. Eylea offers the advantage of a less frequent dosing regimen, typically every 8 weeks after an initial loading phase.

Bevacizumab (Avastin):

Although originally approved for cancer treatment, Bevacizumab is often used off-label for AMD due to its similar mechanism to Ranibizumab and lower cost. It is widely used in clinical practice despite not being specifically approved for AMD.

 2. Photodynamic Therapy (PDT):

Verteporfin (Visudyne):

Approved in 2000, Verteporfin is used in photodynamic therapy to treat predominantly classic subfoveal choroidal neovascularization due to AMD. The drug is injected intravenously and then activated by a low-power laser directed at the affected area of the retina, leading to the destruction of abnormal blood vessels.

Click here to view the Report Description & TOC: https://univdatos.com/reports/age-related-macular-degeneration-market

Conclusion:

The Age-related Macular Degeneration in North America is robust and growing, supported by increasing incidence of AMD supplemented by rising geriatric population, rising adoption of innovative products etc. The development and approval of AMD therapies have significantly advanced the management of this condition, particularly for wet AMD. Anti-VEGF therapies, photodynamic therapy, and nutritional supplements play crucial roles in preserving vision and enhancing the quality of life for individuals with AMD. Ongoing research and emerging treatments hold promise for more effective and lasting solutions, offering hope to millions affected by this age-related condition.

Contact Us:

UnivDatos

Contact Number - +1 978 733 0253

Email - contact@univdatos.com 

Website - www.univdatos.com

Linkedin- https://www.linkedin.com/company/univ-datos-market-insight/mycompany/